CD274 and non-small cell lung carcinoma: Therefore, pembrolizumab as monotherapy has shown durable efficacy regarding OS for the first-line treatment of metastatic NSCLC in adults whose tumours express PD-L1 with a ≥ 50% tumour proportion score (TPS) under controlled clinical trial.